Korean J Med.
2018 Apr;93(2):172-180. 10.3904/kjm.2018.93.2.172.
Biologic Treatment of Severe Asthma
- Affiliations
-
- 1Department of Internal Medicine, Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea. mineyang81@ewha.ac.kr
- KMID: 2435181
- DOI: http://doi.org/10.3904/kjm.2018.93.2.172
Abstract
- Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
